Onychomycosis Market is expected to grow by 2032, Delveinsight

The Onychomycosis Market Insights report from DelveInsight provides a thorough understanding of the Onychomycosis Market size by treatment, epidemiology, emerging therapies, Onychomycosis market share of the various therapies, and the current and forecasted Onychomycosis Market size from 2019 to 2032 divided into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan) regions.

Onychomycosis: An Overview
Onychomycosis is a common fungal nail infection that has been estimated to account for about half of all nail diseases. Although not life-threatening, fungal nail infections are an important public health concern due to their high prevalence, poor response to therapy, and significant clinical, social and financial impact.

Download Onychomycosis sample report here- https://www.delveinsight.com/sample-request/onychomycosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Regions covered in the report
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Key takeaways from Onychomycosis Market Report
• This section includes a glimpse of the Onychomycosis market in the United States. The Onychomycosis market size in 7MM+China was USD 1,278.4 Million in 2020, and the market is estimated to increase during the study period (2018-2030).
• In July 2014, the FDA approved Kerydin (Tavaborole) to treat Onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes. Tavaborole prohibits protein synthesis by inhibition of an aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS).
• The FDA approved Jublia in July 2014 for the Onychomycosis treatment due to Trichophyton rubrum or Trichophyton mentagrophytes. Jublia has been marketed under the brand name Clenafin (Kaken Pharmaceuticals) in Japan since 2014.
• The total Onychomycosis prevalent cases in the 7MM+China were 93,633,252 in 2020.

Onychomycosis Epidemiology Insights
The Onychomycosis epidemiology division's symptoms provide insights into the historical and current patient pool and the forecasted trend for every 7MM+China country. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

Onychomycosis Epidemiology Segmentation in the 7MM
• Diagnosed Onychomycosis prevalent cases
• Onychomycosis Prevalent cases of subtype
• Onychomycosis Prevalence by Severity

Check Onychomycosis Market Share- https://www.delveinsight.com/report-store/onychomycosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Onychomycosis Treatment Market
Several Onychomycosis treatment options are available, including oral antifungals, topical antifungals, and devices. Oral antifungals have higher treatment cure rates and shorter treatment periods than topical treatments but have severe side effects such as hepatotoxicity and drug interactions. Topical treatments have less serious side effects but result in lower cure rates generally and much longer treatment regimens. Besides, new topical formulations are being investigated as faster-acting alternatives to the currently available topical treatments.

Onychomycosis Emerging Drugs
One major player is Moberg Pharma, with its leading product MOB-015. It is a next-generation nail fungus treatment targeting both the over-the-counter (OTC) and prescription markets. The company's patented technology facilitates the delivery of high concentrations of terbinafine into and through the nail. Therefore, this compound has generated enough buzz already in the market since it can address the unmet need for better topical treatments without the risk of systemic side effects.

Onychomycosis Market Drugs
Currently, oral Terbinafine hydrochloride (Lamisil) is the most common treatment for Onychomycosis. These 250mg tablets are taken once a day for 12 weeks. First approved in 1996 by the US FDA, it has been the mainstay with all its generic versions marketed since the patent expiry in 2007. Other components that make up the total revenue generated by systemic therapies include Itraconazole, Griseofulvin, Fluconazole, and etc. These components have been included in the forecast model to calculate the approximate revenue estimates during the study period [2018-2030].

Onychomycosis Market Companies
Onychomycosis market companies includes Pfizer, Bausch Health, Sato Pharmaceutical, Eisai, Moberg Pharma, Blueberry Therapeutics, Mycovia Pharmaceuticals, Meiji Seika Pharma, NovaBiotics, Hallux, and several others.

Learn more information of the report- https://www.delveinsight.com/report-store/onychomycosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Onychomycosis Executive Summary
3. Onychomycosis Competitive Intelligence Analysis
4. Onychomycosis Market Overview at a Glance
5. Onychomycosis: Disease Background and Overview
6. Patient Journey
7. Onychomycosis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Onychomycosis Unmet Needs
10. Key Endpoints of Onychomycosis Treatment
11. Onychomycosis Marketed Products
12. Onychomycosis Emerging Therapies
13. Onychomycosis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Onychomycosis
17. KOL Views
18. Onychomycosis Market Drivers
19. Onychomycosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Request for Webex demo of the report- https://www.delveinsight.com/sample-request/onychomycosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Onychomycosis Market Report Scope
• The report covers the descriptive overview of Onychomycosis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Onychomycosis epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and Onychomycosis emerging therapies is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Onychomycosis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Onychomycosis market

Onychomycosis Market Report Highlights

• In the coming years, the Onychomycosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the Onychomycosis market
• The companies and academics are working to assess challenges and seek opportunities that could influence Onychomycosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing Onychomycosis therapies. The launch of emerging therapies will significantly impact the Onychomycosis market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Onychomycosis
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.